	US 7,514,397 B1
	Methods for inhibition of membrane-fusion-associated events, including Hepatitis B virus transmission
Shawn O'Lin Barney, Cary, N.C. (US); Dennis Michael Lambert, Cary, N.C. (US); and Stephen Robert Petteway, Cary, N.C. (US)
Assigned to Trimeris, Inc., Durham, N.C. (US)
Filed on Jun. 07, 1995, as Appl. No. 8/487,355.
Application 08/487355 is a division of application No. 08/470896, filed on Jun. 06, 1995, granted, now 6,479,055.
Application 08/470896 is a continuation in part of application No. 08/360107, filed on Dec. 20, 1994, granted, now 6,017,536.
Application 08/360107 is a continuation in part of application No. 08/255208, filed on Jun. 07, 1994, granted, now 6,440,656.
Application 08/255208 is a continuation in part of application No. 08/073028, filed on Jun. 07, 1993, granted, now 5,464,933.
Int. Cl. A61K 38/00 (2006.01)

U.S. Cl. 514—2 [514/1; 530/350; 530/826; 439/5; 439/240.2]

37 Claims

1. A method for the inhibition of transmission of a hepatitis B virus to a cell, comprising contacting the virus, in the presence of the cell, with an effective concentration of a peptide having the formula:

X-PLLVLQAGFFLLTRILTIPQSLDSWWTSLNFLGGTTVCLGQNSQSP-Z;

X-PLLVLQAGFFLLTRILTIPQSLDSWWTSLNFLGGT-Z;

X-LLVLQAGFFLLTRILTIPQSLDSWWTSLNFLGGTT-Z;

X-LVLQAGFFLLTRILTIPQSLDSWWTSLNFLGGTTV-Z;

X-LQAGFFLLTRILTIPQSLDSWWTSLNGLGGTTVCL-Z;

X-QAGFFLLTRILTIPQSLDSWWTSLNFLGGTTVCLG-Z;

X-AGFFLLTRILTIPQSLDSWWTSLNFLGGTTVCLGQ-Z;

X-GFFLLTRILTIPQSLDSWWTSLNFLGGTTVCLGQN-Z;

X-FFLLTRILTIPQSLDSWWTSLNFLGGTTVCLGQNS-Z;

X-FLLTRILTIPQSLDSWWTSLNFLGGTTVCLGQNSQ-Z;

X-LLTRILTIPQSLDSWWTSLNFLGGTTVCLGQNSQS-Z;

X-PGYRWMCLRRFIIFLFILLLCLIFLLVLLDYQGMLPVCPLEPGSSTTSTGPCRTCMTT-Z,

X-PGYRWMCLRRFIIFLFILLLCLIFLLVLLDYQGML-Z;

X-GYRWMCLRRFIIFLFILLLCLIFLLVLLDYQGMLP-Z

X-YRWMCLRRFIIFLFILLLCLIFLLVLLDYQGMLPVC-Z;

X-RWMCLRRFIIFLFILLLCLIFLLVLLDYQGMLPVC-Z;

X-WMCLRRFIIFLFILLLCLIFLLVLLDYQGMLPVCP-Z;

X-MCLRRFIIFLFILLLCLIFLLVLLDYQGMLPVCPI-Z;

X-CLRRFIIFLFILLLCLIFLLVLLDYQGMLPVCPLI-Z;

X-LRRFIIFLFILLLCLIFLLVLLDYQGMLPVCPLIP-Z;

X-RRFIIFLFILLLCLIFLLVLLDYQGMLPVCPLIPG-Z;

X-RFIIFLFILLLCLIFLLVLLDYQGMLPVCPLIPGS-Z;

X-FIIFLFILLLCLIFLLVLLDYQGMLPVCPLIPGSS-Z;

IIFLFILLLCLIFLLVLLDYQGMLPVCPLIPGSST-Z

X-IFLFILLLCLIFLLVLLDYQGMLPVCPLIPGSSTT-Z:

X-FLFILLLCLIFLLVLLDYQGMLPVCPLIPGSSTTS-Z:

X-LFILLLCLIFLLVLLDYQGMLPVCPLIPGSSTTST-Z:

X-FILLLCLIFLLVLLDYQGMLPVCPLIPGSSTTSTG-Z;

X-ILLLCLIFLLVLLDYQGMLPVCPLIPGSSTTSTGP-Z:

X-LLLCLIFLLVLLDYQGMLPVCPLIPGSSTTSTGPC-Z;

X-LLCLIFLLVLLDYQGMLPVCPLIPGSSTTSTGPCR-Z;

X-LCLIFLLVLLDYQGMLPVCPLIPGSSTTSTGPCRT-Z;

X-CLIFLLVLLDYQGMLPVCPLIPGSSTTSTGPCRTC-Z;

X-LIFLLVLLDYQGMLPVCPLIPGSSTTSTGPCRTCM-Z; or

X-IFLLVLLDYQGMLPVCPLIPGSSTTSTGPCRTCMT-Z;

(SEQ ID NOS: 239-273, respectively)

in which:

amino acid residues are presented by the single-letter code;

X comprises an amino group, an acetyl group, a 9-fluorenylmethoxy-carbonyl group, a hydrophobic group, or a macromolecule carrier group;

Z comprises a carboxyl group, an amido group, a hydrophobic group, or a macromolecular carrier group for an effective period of time so that infection of the cell by the virus is inhibited.